262 related articles for article (PubMed ID: 19954842)
1. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine.
Choi YS; Lee JY; Suh JS; Kwon YM; Lee SJ; Chung JK; Lee DS; Yang VC; Chung CP; Park YJ
Biomaterials; 2010 Feb; 31(6):1429-43. PubMed ID: 19954842
[TBL] [Abstract][Full Text] [Related]
2. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
Reich SJ; Fosnot J; Kuroki A; Tang W; Yang X; Maguire AM; Bennett J; Tolentino MJ
Mol Vis; 2003 May; 9():210-6. PubMed ID: 12789138
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study.
Park YJ; Liang JF; Ko KS; Kim SW; Yang VC
J Gene Med; 2003 Aug; 5(8):700-11. PubMed ID: 12898639
[TBL] [Abstract][Full Text] [Related]
4. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters).
Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN
J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950
[TBL] [Abstract][Full Text] [Related]
5. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
Park K; Lee MY; Kim KS; Hahn SK
Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
[TBL] [Abstract][Full Text] [Related]
6. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
[TBL] [Abstract][Full Text] [Related]
8. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
Wang XL; Xu R; Lu ZR
J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma.
Guo B; Zhang Y; Luo G; Li L; Zhang J
Anat Rec (Hoboken); 2009 May; 292(5):633-9. PubMed ID: 19382240
[TBL] [Abstract][Full Text] [Related]
10. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Fisch G; Dames S; Löffler K; Fechtner M; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Aug; 13(16):1222-34. PubMed ID: 16625243
[TBL] [Abstract][Full Text] [Related]
11. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
[TBL] [Abstract][Full Text] [Related]
12. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system.
Kim SW; Kim NY; Choi YB; Park SH; Yang JM; Shin S
J Control Release; 2010 May; 143(3):335-43. PubMed ID: 20079391
[TBL] [Abstract][Full Text] [Related]
13. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.
Urban-Klein B; Werth S; Abuharbeid S; Czubayko F; Aigner A
Gene Ther; 2005 Mar; 12(5):461-6. PubMed ID: 15616603
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery.
Golzio M; Mazzolini L; Moller P; Rols MP; Teissié J
Gene Ther; 2005 Feb; 12(3):246-51. PubMed ID: 15592423
[TBL] [Abstract][Full Text] [Related]
15. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
[TBL] [Abstract][Full Text] [Related]
16. A non-covalent peptide-based strategy for siRNA delivery.
Crombez L; Charnet A; Morris MC; Aldrian-Herrada G; Heitz F; Divita G
Biochem Soc Trans; 2007 Feb; 35(Pt 1):44-6. PubMed ID: 17233597
[TBL] [Abstract][Full Text] [Related]
17. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs.
Kim EJ; Shim G; Kim K; Kwon IC; Oh YK; Shim CK
J Gene Med; 2009 Sep; 11(9):791-803. PubMed ID: 19569085
[TBL] [Abstract][Full Text] [Related]
19. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach.
Tao J; Tu YT; Huang CZ; Feng AP; Wu Q; Lian YJ; Zhang LX; Zhang XP; Shen GX
Br J Dermatol; 2005 Oct; 153(4):715-24. PubMed ID: 16181451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]